Quick theoretical question...Solid tumours have long been an issue when it comes to CAR-T capabilities. I understand the use of cf33 to induce CD19 expression on solid tumour cell lines then further treating with CD19 targeting therapies. However in melanoma for example, HER2-CAR T targetting cells have very limited effect against HER2+ Tu in murine. A lot of people have put this down to matter of a more difficult and intricate tumour microenvironment? So does that mean cf33 just induces an extreme expression of target antigen (cd19) and this how it can get an upperhand on a cell line that may express 100% but not at this extreme amount? TIA, GLTA
- Forums
- ASX - By Stock
- IMU
- Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-108
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.6¢ |
Change
0.005(9.80%) |
Mkt cap ! $400.5M |
Open | High | Low | Value | Volume |
5.1¢ | 5.7¢ | 5.1¢ | $1.368M | 25.32M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 1260245 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 97949 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 1426849 | 0.055 |
9 | 738039 | 0.054 |
14 | 2063000 | 0.053 |
8 | 1586922 | 0.052 |
12 | 1087112 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 109458 | 9 |
0.057 | 1026785 | 12 |
0.058 | 1481626 | 10 |
0.059 | 1415548 | 10 |
0.060 | 2243724 | 23 |
Last trade - 15.09pm 10/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online